Seattle Genetics Inc. [NASDAQ: SGEN] jumped around 4.73 points on Wednesday, while shares priced at $195.69 at the close of the session, up 2.48%.
Seattle Genetics Inc. stock is now 71.27% up from its year-to-date (YTD) trading value. SGEN Stock saw the intraday high of $198.00 and lowest of $191.32 per share. The company’s 52-week high price is 192.30, which means current price is +116.06% above from all time high which was touched on 09/30/20.
Compared to the average trading volume of 1.00M shares, SGEN reached a trading volume of 1487996 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Seattle Genetics Inc. [SGEN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SGEN shares is $189.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SGEN stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Seattle Genetics Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on September 22, 2020. While these analysts kept the previous recommendation, Berenberg raised their target price to Buy. The new note on the price target was released on August 24, 2020, representing the official price target for Seattle Genetics Inc. stock. Previously, the target price had yet another raise from $175 to $200, while H.C. Wainwright kept a Buy rating on SGEN stock.
The Average True Range (ATR) for Seattle Genetics Inc. is set at 5.66, with the Price to Sales ratio for SGEN stock in the period of the last 12 months amounting to 32.53. The Price to Book ratio for the last quarter was 18.71, with the Price to Cash per share for the same quarter was set at 5.31.
How has SGEN stock performed recently?
Seattle Genetics Inc. [SGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.16. With this latest performance, SGEN shares gained by 23.59% in over the last four-week period, additionally plugging by 75.92% over the last 6 months – not to mention a rise of 127.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SGEN stock in for the last two-week period is set at 74.99, with the RSI for the last a single of trading hit 82.13, and the three-weeks RSI is set at 70.27 for Seattle Genetics Inc. [SGEN]. The present Moving Average for the last 50 days of trading for this stock 165.16, while it was recorded at 188.31 for the last single week of trading, and 141.18 for the last 200 days.
Seattle Genetics Inc. [SGEN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seattle Genetics Inc. [SGEN] shares currently have an operating margin of -24.06 and a Gross Margin at +95.21. Seattle Genetics Inc.’s Net Margin is presently recorded at -17.31.
Return on Total Capital for SGEN is now -13.67, given the latest momentum, and Return on Invested Capital for the company is -9.86. Return on Equity for this stock declined to -10.07, with Return on Assets sitting at -8.55. When it comes to the capital structure of this company, Seattle Genetics Inc. [SGEN] has a Total Debt to Total Equity ratio set at 4.11. Additionally, SGEN Total Debt to Total Capital is recorded at 3.94, with Total Debt to Total Assets ending up at 3.49. Long-Term Debt to Equity for the company is recorded at 3.60, with the Long-Term Debt to Total Capital now at 3.46.
Reflecting on the efficiency of the workforce at the company, Seattle Genetics Inc. [SGEN] managed to generate an average of -$98,847 per employee. Receivables Turnover for the company is 4.80 with a Total Asset Turnover recorded at a value of 0.49.Seattle Genetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.70.
Earnings analysis for Seattle Genetics Inc. [SGEN]
With the latest financial reports released by the company, Seattle Genetics Inc. posted -0.55/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -52.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SGEN.
Insider trade positions for Seattle Genetics Inc. [SGEN]
There are presently around $31,520 million, or 94.00% of SGEN stock, in the hands of institutional investors. The top three institutional holders of SGEN stocks are: BAKER BROS. ADVISORS LP with ownership of 47,269,424, which is approximately -5.575% of the company’s market cap and around 0.90% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 18,697,224 shares of the stock with an approximate value of $3.66 billion in SGEN stocks shares; and BLACKROCK INC., currently with $2.3 billion in SGEN stock with ownership of nearly 6.524% of the company’s market capitalization.
Positions in Seattle Genetics Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 313 institutional holders increased their position in Seattle Genetics Inc. [NASDAQ:SGEN] by around 9,619,302 shares. Additionally, 156 investors decreased positions by around 13,297,025 shares, while 48 investors held positions by with 138,152,318 shares. The mentioned changes placed institutional holdings at 161,068,645 shares, according to the latest SEC report filing. SGEN stock had 129 new institutional investments in for a total of 3,009,831 shares, while 25 institutional investors sold positions of 1,588,854 shares during the same period.